Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer

Table 1 Extent of lymphadenectomy D1 vs D2 according to the JRSGC[5,6]

	D1	D2
Upper third	1-2-3-4	D1+5-6-7-8-9-10-11-110
Middle third	1-3-4-5-6	D1+2-7-8 -9 -10 -11
Lower third	3-4-5-6	D1+1-7-8-9

JRSGC: Japanese Research Society for the Study of Gastric Cancer.

Table 2 Patient characteristics

	Arm A (n = 34)	Arm B (n = 35)
Age (yr): median (range)	57 (25-75)	59 (39-76)
Male (%)	68	71
PS 0/1/2 (%)	91/6/3	86/14/0
Tumor site (%)
Cardia	21	20
Fundus/body	38	40
Antrum/pylorus	41	40
Stage (by EUS + CT scan)
IB	2	1
II	14	13
III	18	21

EUS: Endoscopic ultrasound; CT: Computerized tomography.

Table 3 Details of surgical procedures and pathology

	Arm A (n = 32)	Arm B (n = 35)
Complete resection R0 (%)	29 (85)	32 (91)
Non-radical resection (%)	2 (5.8)	2 (5.7)
No resection pM1 (peritoneum) (%)	1 (2.9)	1 (2.8)
pCR n (%)	4 (11.7)	NA
pPR n (%)	18 (55)	NA
Total gastrectomy	20	24
Subtotal gastrectomy	11	10
D-2 lymphadenectomy	29	31
D-3 lymphadenectomy	-	2
Excised lymph nodes median (range)	20 (9-39)	26 (13-76)
Metastatic lymph nodes median (range)	1 (0-23)	5 (0-50)

pCR: Pathological complete response; pPR: Pathological partial response; NA: Not available.

Table 4 Postoperative morbidity and mortality, ranked according to Dindo et al[5]

Type of complication	Arm A (n = 32)	Arm B (n = 35)
Anastomotic leak	1-IVb	1-IVb
Abdominal abscess	2-IIIa	1-IIIa
Infected peritoneal collection	1-IIIa	1-IIIa
Anastomotic bleeding	1-IIIb (re-operation)	-
Pneumonia requiring ICU	1-IVa	3-IVa-IVa, V (re-operation, death)
Pulmonary embolism	1-II	-
Urinary infection	1-II	-
Fever of unknown origin	1-II	-
Mediastinal infected collection + MOF	-	1-V (re-operation, death)
Central venous catheter-related blood stream infection	-	2-II
Totala	9 (28.5%), 1 re-operation	9 (25.7%), 2 re-operations, 1 death

^aP = 0.86. ICU: Intensive care unit; MOF: Multiple organ failure.

Table 5 Treatment administration and SAEs

	Arm A (n = 33)	Arm B (n = 23)
Total number of cycles	118	71
Causes of treatment failure
Progression of disease	1	0
G4 toxicity	2	6
Death	1	1
Patient refusal	1	1
Investigator’s decision	2	3
Other	1	1
Total	8	12
Severe adverse events (% of cycles)a	13 (11)	16 (23)
No. of patients involved (% of pts. treated)b	10 (30)	14 (60)

^aP = 0.07,

^bP = 0.15. SAE: Severe adverse event.